273 related articles for article (PubMed ID: 36631359)
21. SARS-CoV-2 bivalent mRNA vaccine with broad protection against variants of concern.
Ma Q; Li M; Ma L; Zhang C; Zhang H; Zhong H; Wen J; Wang Y; Yan Z; Xiong W; Wu L; Guo J; Yang W; Yang Z; Zhang B
Front Immunol; 2023; 14():1195299. PubMed ID: 37292197
[TBL] [Abstract][Full Text] [Related]
22. Intranasal inoculation of an MVA-based vaccine induces IgA and protects the respiratory tract of hACE2 mice from SARS-CoV-2 infection.
Americo JL; Cotter CA; Earl PL; Liu R; Moss B
Proc Natl Acad Sci U S A; 2022 Jun; 119(24):e2202069119. PubMed ID: 35679343
[TBL] [Abstract][Full Text] [Related]
23. A Recombinant VSV-Based Bivalent Vaccine Effectively Protects against Both SARS-CoV-2 and Influenza A Virus Infection.
Ao Z; Ouyang MJ; Olukitibi TA; Warner B; Vendramelli R; Truong T; Meilleur C; Zhang M; Kung S; Fowke KR; Kobasa D; Yao X
J Virol; 2022 Sep; 96(18):e0133722. PubMed ID: 36069551
[TBL] [Abstract][Full Text] [Related]
24. mRNA-1273 and Ad26.COV2.S vaccines protect against the B.1.621 variant of SARS-CoV-2.
Darling TL; Ying B; Whitener B; VanBlargan LA; Bricker TL; Liang CY; Joshi A; Bamunuarachchi G; Seehra K; Schmitz AJ; Halfmann PJ; Kawaoka Y; Elbashir SM; Edwards DK; Thackray LB; Diamond MS; Boon ACM
Med; 2022 May; 3(5):309-324.e6. PubMed ID: 35584653
[TBL] [Abstract][Full Text] [Related]
25. An intranasal lentiviral booster reinforces the waning mRNA vaccine-induced SARS-CoV-2 immunity that it targets to lung mucosa.
Vesin B; Lopez J; Noirat A; Authié P; Fert I; Le Chevalier F; Moncoq F; Nemirov K; Blanc C; Planchais C; Mouquet H; Guinet F; Hardy D; Vives FL; Gerke C; Anna F; Bourgine M; Majlessi L; Charneau P
Mol Ther; 2022 Sep; 30(9):2984-2997. PubMed ID: 35484842
[TBL] [Abstract][Full Text] [Related]
26. Antibody Avidity and Neutralizing Response against SARS-CoV-2 Omicron Variant after Infection or Vaccination.
Dapporto F; Marchi S; Leonardi M; Piu P; Lovreglio P; Decaro N; Buonvino N; Stufano A; Lorusso E; Bombardieri E; Ruello A; Viviani S; Molesti E; Trombetta CM; Manenti A; Montomoli E
J Immunol Res; 2022; 2022():4813199. PubMed ID: 36093434
[TBL] [Abstract][Full Text] [Related]
27. Design, immunogenicity, and efficacy of a pan-sarbecovirus dendritic-cell targeting vaccine.
Coléon S; Wiedemann A; Surénaud M; Lacabaratz C; Hue S; Prague M; Cervantes-Gonzalez M; Wang Z; Ellis J; Sansoni A; Pierini C; Bardin Q; Fabregue M; Sharkaoui S; Hoest P; Dupaty L; Picard F; El Hajj M; Centlivre M; Ghosn J; ; Thiébaut R; Cardinaud S; Malissen B; Zurawski G; Zarubica A; Zurawski SM; Godot V; Lévy Y
EBioMedicine; 2022 Jun; 80():104062. PubMed ID: 35594660
[TBL] [Abstract][Full Text] [Related]
28. A mRNA Vaccine Encoding for a RBD 60-mer Nanoparticle Elicits Neutralizing Antibodies and Protective Immunity Against the SARS-CoV-2 Delta Variant in Transgenic K18-hACE2 Mice.
Brandys P; Montagutelli X; Merenkova I; Barut GT; Thiel V; Schork NJ; Trüeb B; Conquet L; Deng A; Antanasijevic A; Lee HK; Valière M; Sindhu A; Singh G; Herold J
Front Immunol; 2022; 13():912898. PubMed ID: 35874687
[TBL] [Abstract][Full Text] [Related]
29. Receptor binding domain proteins of SARS-CoV-2 variants produced in Nicotiana benthamiana elicit neutralizing antibodies against variants of concern.
Khorattanakulchai N; Manopwisedjaroen S; Rattanapisit K; Panapitakkul C; Kemthong T; Suttisan N; Srisutthisamphan K; Malaivijitnond S; Thitithanyanont A; Jongkaewwattana A; Shanmugaraj B; Phoolcharoen W
J Med Virol; 2022 Sep; 94(9):4265-4276. PubMed ID: 35615895
[TBL] [Abstract][Full Text] [Related]
30. Protective prototype-Beta and Delta-Omicron chimeric RBD-dimer vaccines against SARS-CoV-2.
Xu K; Gao P; Liu S; Lu S; Lei W; Zheng T; Liu X; Xie Y; Zhao Z; Guo S; Tang C; Yang Y; Yu W; Wang J; Zhou Y; Huang Q; Liu C; An Y; Zhang R; Han Y; Duan M; Wang S; Yang C; Wu C; Liu X; She G; Liu Y; Zhao X; Xu K; Qi J; Wu G; Peng X; Dai L; Wang P; Gao GF
Cell; 2022 Jun; 185(13):2265-2278.e14. PubMed ID: 35568034
[TBL] [Abstract][Full Text] [Related]
31. A bivalent vaccine containing D614G and BA.1 spike trimer proteins or a BA.1 spike trimer protein booster shows broad neutralizing immunity.
Du P; Li N; Xiong X; Tang S; Dai Q; Liu Z; Wang T; Gu X; Zhou Z
J Med Virol; 2022 Sep; 94(9):4287-4293. PubMed ID: 35614524
[TBL] [Abstract][Full Text] [Related]
32. SARS-CoV-2 Omicron BA.1 Challenge after Ancestral or Delta Infection in Mice.
Baz M; Deshpande N; Mackenzie-Kludas C; Mordant F; Anderson D; Subbarao K
Emerg Infect Dis; 2022 Nov; 28(11):2352-2355. PubMed ID: 36191630
[TBL] [Abstract][Full Text] [Related]
33. The impact of spike mutated variants of SARS-CoV2 [Alpha, Beta, Gamma, Delta, and Lambda] on the efficacy of subunit recombinant vaccines.
Mohammadi M; Shayestehpour M; Mirzaei H
Braz J Infect Dis; 2021; 25(4):101606. PubMed ID: 34428473
[TBL] [Abstract][Full Text] [Related]
34. Elicitation of Broadly Neutralizing Antibodies against B.1.1.7, B.1.351, and B.1.617.1 SARS-CoV-2 Variants by Three Prototype Strain-Derived Recombinant Protein Vaccines.
Yang Y; Zang J; Xu S; Zhang X; Yuan S; Wang H; Lavillette D; Zhang C; Huang Z
Viruses; 2021 Jul; 13(8):. PubMed ID: 34452287
[TBL] [Abstract][Full Text] [Related]
35. Human serum from SARS-CoV-2-vaccinated and COVID-19 patients shows reduced binding to the RBD of SARS-CoV-2 Omicron variant.
Schubert M; Bertoglio F; Steinke S; Heine PA; Ynga-Durand MA; Maass H; Sammartino JC; Cassaniti I; Zuo F; Du L; Korn J; Milošević M; Wenzel EV; Krstanović F; Polten S; Pribanić-Matešić M; Brizić I; Baldanti F; Hammarström L; Dübel S; Šustić A; Marcotte H; Strengert M; Protić A; Piralla A; Pan-Hammarström Q; Čičin-Šain L; Hust M
BMC Med; 2022 Mar; 20(1):102. PubMed ID: 35236358
[TBL] [Abstract][Full Text] [Related]
36. Omicron-specific mRNA vaccine induced cross-protective immunity against ancestral SARS-CoV-2 infection with low neutralizing antibodies.
Shen KY; Yang CH; Chen CT; Ho HM; Chiu FF; Huang CY; Liao HC; Hsu CW; Yu GY; Liao CL; Chen HW; Huang MH; Liu SJ
J Med Virol; 2023 Jan; 95(1):e28370. PubMed ID: 36458553
[TBL] [Abstract][Full Text] [Related]
37. Subunit vaccine raised against the SARS-CoV-2 spike of Delta and Omicron variants.
Feng S; Fan Z; Zhou K; Ma S; Liang M; Zhang H; Xie Y; Ha Z; Jin N; Lu H
J Med Virol; 2023 Oct; 95(10):e29160. PubMed ID: 37822266
[TBL] [Abstract][Full Text] [Related]
38. A novel RBD-protein/peptide vaccine elicits broadly neutralizing antibodies and protects mice and macaques against SARS-CoV-2.
Wang S; Wang CY; Kuo HK; Peng WJ; Huang JH; Kuo BS; Lin F; Liu YJ; Liu Z; Wu HT; Ding S; Hou KL; Cheng J; Yang YT; Jiang MH; Wang MS; Chen T; Xia WG; Lin E; Hung CH; Chen HJ; Shih Z; Lin YL; Ryan V; Hu MM; Heppner DG; Malherbe DC; Periasamy S; Kuzmina N; Subramani C; Hellerstein M; Monath TP; Rumyantsev A; Bukreyev A; Guirakhoo F
Emerg Microbes Infect; 2022 Dec; 11(1):2724-2734. PubMed ID: 36287714
[TBL] [Abstract][Full Text] [Related]
39. Evaluating Antibody Mediated Protection against Alpha, Beta, and Delta SARS-CoV-2 Variants of Concern in K18-hACE2 Transgenic Mice.
Wong TY; Horspool AM; Russ BP; Ye C; Lee KS; Winters MT; Bevere JR; Miller OA; Rader NA; Cooper M; Kieffer T; Sourimant J; Greninger AL; Plemper RK; Denvir J; Cyphert HA; Barbier M; Torrelles JB; Martinez I; Martinez-Sobrido L; Damron FH
J Virol; 2022 Mar; 96(6):e0218421. PubMed ID: 35080423
[TBL] [Abstract][Full Text] [Related]
40. Skin-patch delivered subunit vaccine induces broadly neutralising antibodies against SARS-CoV-2 variants of concern.
McMillan CLD; Amarilla AA; Modhiran N; Choo JJY; Azuar A; Honeyman KE; Khromykh AA; Young PR; Watterson D; Muller DA
Vaccine; 2022 Aug; 40(34):4929-4932. PubMed ID: 35871873
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
